Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833008 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
A Phase 1 study of Advanced Solid Tumor, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 13
- Study locations
NCT06833008: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Ipsen.
NCT06833008 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Ipsen. The registered enrollment target is 85 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (56% lower). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06833008, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.
Conditions Studied
Interventions
- DRUG IPN01195
Study Locations (13)
Other
- Centre Léon Bérard - Lyon - Lyon
- Paris Saint-Louis - Paris
- IGR-Villejuif - Villejuif
- Istituto Nazionale dei Tumori - Milan
- Istituto Nazionale Tumori IRCCS - Fondazione Pascale - Naples
- Val D'Hebron - Barcelona
- Hospital Universitario Quirónsalud Madrid - Madrid
- M.D. Anderson Center Madrid - Madrid
Michigan
- START Mid-West - Grand Rapids
Tennessee
- Sarah Cannon Research Institute (SCRI) - Nashville - Nashville
Texas
- Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas - Dallas
Utah
- START Mountan Region - West Valley City
Virginia
- Virginia Cancer Specialist- Fairfax - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2028-10-03 |
| Phase | Phase 1 |
What NCT06833008 shows while recruiting
NCT06833008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IPN01195 is the first listed.
NCT06833008 lists 13 locations in 6 states (Other, Michigan, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06833008 about?
NCT06833008 is a clinical study titled "A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours". The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places...
What is the current status of trial NCT06833008?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2025-03-14. Estimated completion is 2028-10-03.
What conditions does trial NCT06833008 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06833008?
The interventions under investigation include: IPN01195 (DRUG).
Who is sponsoring clinical trial NCT06833008?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06833008 being conducted?
This trial has 13 study locations across Michigan, Tennessee, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06833008's enrollment target sits among peer trials
85 133rd of 189 higher than 57 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI